Dashboard
Manage Tickers

CUECue Biopharma, Inc.

Nasdaq cuebiopharma.com


$ 0.59 $ -0.04 (-6.35 %)    

Friday, 06-Sep-2024 14:02:27 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 448.85 $ -12.38 (-2.68 %)
DIA $ 404.28 $ -4.32 (-1.06 %)
SPY $ 539.93 $ -10.03 (-1.82 %)
TLT $ 99.62 $ 0.07 (0.07 %)
GLD $ 230.52 $ -1.26 (-0.54 %)
$ 0.63
$ 0.62
$ 0.64 x 538
$ 0.59 x 100
$ 0.59 - $ 0.62
$ 0.58 - $ 3.25
191,671
na
30.65M
$ 1.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-21-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-16-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-09-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-14-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-13-2018 06-30-2018 10-Q
26 05-14-2018 03-31-2018 10-Q
27 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cue-biopharma-to-present-at-the-promise-of-interleukin-2-therapy-conference-september-6-2024
Cue Biopharma To Present At The Promise Of...
09/03/2024 12:17:00

Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics ...

stifel-maintains-buy-on-cue-biopharma-lowers-price-target-to-4
Stifel Maintains Buy on Cue Biopharma, Low...
08/20/2024 11:36:50

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.

cue-biopharma-q2-2024-gaap-eps-020-beats-024-estimate-sales-2658m-beat-1293m-estimate
Cue Biopharma Q2 2024 GAAP EPS $(0.20) Bea...
08/19/2024 20:12:54

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) ...

jmp-securities-maintains-market-outperform-on-cue-biopharma-lowers-price-target-to-2
JMP Securities Maintains Market Outperform...
07/26/2024 18:12:44

JMP Securities analyst Reni Benjamin maintains Cue Biopharma (NASDAQ:CUE) with a Market Outperform and lowers the price targ...

piper-sandler-maintains-overweight-on-cue-biopharma-lowers-price-target-to-3
Piper Sandler Maintains Overweight on Cue ...
07/26/2024 13:53:39

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and lowers the price target fro...

cue-biopharma-announces-strategic-prioritization-of-autoimmune-programs-anticipates-annualized-capital-and-workforce-requirements-to-be-reduced-by-25-expects-to-reduce-its-fy25-operating-expenses-by-25-to-a-projected-annual-cash-burn-based-upon-current-assumptions-of-30m
Cue Biopharma Announces Strategic Prioriti...
07/25/2024 20:36:05

Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncolo...

cue-biopharma-presents-updated-data-from-phase-1-trial-of-cue-101-in-recurrentmetastatic-hpv-head-and-neck-cancer-at-asco-2024
Cue Biopharma Presents Updated Data From P...
06/04/2024 12:10:38

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+...

cue-biopharma-q1-2024-adj-eps-025-beats-028-estimate
Cue Biopharma Q1 2024 Adj EPS $(0.25) Beat...
05/09/2024 20:57:19

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) ...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
05/02/2024 20:31:10

forecasting-the-future-4-analyst-projections-for-cue-biopharma
Forecasting The Future: 4 Analyst Projecti...
04/09/2024 14:01:21

stifel-maintains-buy-on-cue-biopharma-maintains-8-price-target
Stifel Maintains Buy on Cue Biopharma, Mai...
04/09/2024 12:46:28

Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and maintains $8 price target.

oppenheimer-maintains-outperform-on-cue-biopharma-maintains-10-price-target
Oppenheimer Maintains Outperform on Cue Bi...
04/09/2024 12:22:07

Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.

cue-biopharma-q1-eps-028-misses-027-estimate-sales-182m-beat-113m-estimate
Cue Biopharma Q1 EPS $(0.28) Misses $(0.27...
04/08/2024 20:06:32

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.27...

piper-sandler-reiterates-overweight-on-cue-biopharma-maintains-8-price-target
Piper Sandler Reiterates Overweight on Cue...
04/03/2024 16:01:11

Piper Sandler analyst Edward Tenthoff reiterates Cue Biopharma (NASDAQ:CUE) with a Overweight and maintains $8 price target.

why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Clover Health Investments Shares Are T...
03/13/2024 17:18:56

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

jefferies-initiates-coverage-on-cue-biopharma-with-buy-rating-announces-price-target-of-6
Jefferies Initiates Coverage On Cue Biopha...
03/13/2024 13:02:38

Jefferies analyst Maury Raycroft initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Targ...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
01/01/2024 21:30:54

cue-biopharma-q3-eps-024-beats-034-estimate-sales-210m-beat-113m-estimate
Cue Biopharma Q3 EPS $(0.24) Beats $(0.34)...
11/09/2023 22:38:06

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.34) ...

piper-sandler-maintains-overweight-on-cue-biopharma-raises-price-target-to-8
Piper Sandler Maintains Overweight on Cue ...
11/06/2023 15:40:59

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and raises the price target fro...

cue-biopharma-presents-new-data-from-phase-1-trials-of-cue-101-in-head-and-neck-cancer-and-cue-102-in-wilms-tumor-1-positive-cancers-at-sitc-2023
Cue Biopharma Presents New Data From Phase...
11/03/2023 16:04:09

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION